Canon Medical Systems USA Reports Partnership With Zebra Medical Vision to Further Expand AI Offerings

Canon Medical Systems USA, Inc. has announced they are partnering with Zebra Medical Vision (Zebra-Med) to offer its AI1™ automated imaging analysis solutions to help clinicians in the U.S. provide faster, accurate diagnoses for optimized patient care.

Zebra Medical Vision technology provides cloud-based analysis of images through FDA-cleared AI solutions, trained on millions of patient scans to triage acute medical conditions, detect incidental findings, and stratify risk. This partnership with Canon Medical Systems USA, Inc. marks the introduction of Zebra-Med’s solution into the modality space, bringing AI analysis closer to the point of care.

“We are excited about the partnership with Canon Medical Systems USA, Inc., a company taking innovative and proactive steps to ensure AI adoption for better patient care. The integration of our solution into the modality space allows us to realize Zebra-Med’s vision of improving patient care at scale. Thanks to the strong product integration between the two companies, Canon Medical customers can save crucial time reaching acute cases faster, and enjoy AI insights directly in their workflow seamlessly,” said Ohad Arazi, CEO of Zebra Medical Vision.

“By partnering with Zebra-Med, Canon Medical Systems USA, Inc. is further proving our leadership and commitment to innovation in diagnostic imaging through accessible AI,” said Satrajit Misra, senior vice president, Marketing and Strategic Development, & acting vice president, Sales, Canon Medical Systems USA, Inc. “As we continue to expand our AI offerings across systems and modalities, we’re elevating the diagnostic imaging capabilities for our customers and providing more opportunities to improve patient care than ever before.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version